Key result
Mayo ATTR-CM score diagnostic performance evaluated against established scores and biomarkers in suspected cardiac amyloidosis.
Why the study?
Does the Mayo ATTR-CM score improve diagnostic performance compared to previous tools (IWT score, AMYLI score, and cardiac biomarkers) in patients with suspected cardiac amyloidosis?
Cohort
Does the Mayo ATTR-CM score improve diagnostic performance compared to previous tools (IWT score, AMYLI score, and cardiac biomarkers) in patients with suspected cardiac amyloidosis?
Several scores were developed to help the diagnosis of cardiac amyloidosis (CA). The most recent one, being the Mayo transthyretin amyloidosis cardiomyopathy (ATTR-CM) score, was not externally validated. We compared the diagnostic performance of the ATTR-CM score with previous tools (increased wall thickness [IWT] score, AMYLoidosis Index [AMYLI] score, and cardiac biomarkers) in a cohort of patients evaluated for a suspicion of CA.
No takes yet. Share an insight, caveat, or question.
Bonfioli et al. (2024) conducted a cohort in suspected cardiac amyloidosis. Mayo ATTR-CM score vs. IWT score, AMYLI score, and cardiac biomarkers was evaluated on diagnostic performance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: